RxDoctor Payments Data

Gary Reasor, MD

Interventional Pain Medicine · Louisville, KYNPI 1457356263

Payments from drug & device makers

What this record shows

It is spread thinly across 22 manufacturers, the largest accounting for just 21.9%. Reporting peaked in 2024 at $3,630 and has fallen 82.7% since, to $626 in 2025.

$9,048in general payments, 2019–2025

Across 194 payments — averaging $46.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Spinal Simplicity, LLC$2K
  • Boston Scientific$2K
  • Vertiflex, Inc.$899
  • Abbott$594
  • Si-bone, Inc.$491
  • plus $2K from 16 others

What the payments were for

  • Travel & lodging$4,58851%
  • Food & beverage$4,46049%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,048 in reported general payments places this provider in the 80th percentile of 55 interventional pain medicine providers in Kentucky.

See all interventional pain medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$668,221
Medicare patients
540
Services billed
275,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl259$318,314
Xtampza ErOxycodone Myristate151$206,026
Oxycodone Hcl2,332$111,645
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen2,041$75,277
Fentanyl434$73,430
Oxymorphone Hcl ErOxymorphone Hcl70$60,958
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,150$59,290
Morphine Sulfate ErMorphine Sulfate510$27,870
LinzessLinaclotide21$17,277
Hydromorphone Hcl344$11,465
Morphine Sulfate162$9,285
MovantikNaloxegol Oxalate14$7,240
Buprenorphine16$4,799
Methadone Hcl178$4,791
Tizanidine Hcl425$4,776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$17$206,026151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 55 interventional pain medicine providers in Kentucky.

Other interventional pain medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →